MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Transition Therapeutics Company Profile (NASDAQ:TTHI)

Consensus Ratings for Transition Therapeutics (NASDAQ:TTHI) (?)
Ratings Breakdown: 2 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.50 (102.70% upside)

Analysts' Ratings History for Transition Therapeutics (NASDAQ:TTHI)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Canaccord GenuityReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Transition Therapeutics (NASDAQ:TTHI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
9/15/2015Q415($0.39)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q315($0.20)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015($0.24)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q312($0.18)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/26/2014($0.28)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014($0.07)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013($0.11)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Transition Therapeutics (NASDAQ:TTHI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Transition Therapeutics (NASDAQ:TTHI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Transition Therapeutics (NASDAQ:TTHI)
DateHeadline
05/27/16 01:38 PMTransition Therapeutics Ord (NASDAQ:TTHI) Short Interest Decreased By 12.21% - Wall Street Hints and News - Transition Therapeutics Ord (NASDAQ:TTHI) Short Interest Decreased By 12.21%Wall Street Hints and NewsThe short interest to Transition Therapeutics Ord's float is 1.27%. The stock is up 2.63% or $0.02 after the news, hitting $0.78 per share. About 6,206 shares traded hands. Transition Therapeutics Inc (USA) (NASDAQ:TTHI) has declined 61.42% since ...
05/24/16 02:03 PMTransition Therapeutics, Inc. (TTHI) Broker Price Targets For The Coming Week - Share Trading News - Transition Therapeutics, Inc. (TTHI) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Transition Therapeutics, Inc. (TTHI). The latest reports which are currently in issue on Monday 23rd of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/20/16 01:47 PMRevenue Update on Transition Therapeutics Inc (USA)(NASDAQ:TTHI) - Trade Calls - Revenue Update on Transition Therapeutics Inc (USA)(NASDAQ:TTHI)Trade CallsTransition Therapeutics Inc (USA)(NASDAQ:TTHI) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during After-hours on May 11, 2016. Earnings per share were $-0.11. Transition Therapeutics Inc (USA) (TTHI) made into the ...
05/12/16 08:19 AMPhil Kessel scores twice as Pittsburgh Penguins eliminate Washington Capitals with 4-3 victory in OT - Transition Therapeutics posts loss of $3 million in 3rd quarter... TORONTO - TORONTO (AP) _ Transition Therapeutics Inc. (TTHI) on Wednesday reported a loss of $3 million in its fiscal third quarter. Barrel of crude surges to highest level in 2016 on U.S ...
05/11/16 03:23 PMTransition Therapeutics posts 3Q loss -
05/11/16 03:01 PMTransition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results - [PR Newswire] - TORONTO, May 11, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel ...
05/09/16 03:01 PMTransition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST - [PR Newswire] - TORONTO, May 9, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 11th, 2016 at 4:30 P.M. EST to discuss Third Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 698-9012 (North America) and (303) 223-4374 (International). A webcast is also available at www.transitiontherapeutics.com A replay of the conference call will be available on Transition's website for seven days following the call. Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS, metabolic diseases and androgen deficiency indications.
04/29/16 08:32 AMTransition Therapeutics Ord (NASDAQ:TTHI) Shorted Shares Decreased By 8.42% - B.O.D.Y Confidential - Transition Therapeutics Ord (NASDAQ:TTHI) Shorted Shares Decreased By 8.42%B.O.D.Y ConfidentialThe short interest to Transition Therapeutics Ord's float is 1.39%. The stock increased 0.59% or $0.005 on April 28, hitting $0.85. About 13,682 shares traded hands. Transition Therapeutics Inc (USA) (NASDAQ:TTHI) has declined 57.29% since September 22 ...
04/26/16 08:48 AMTransition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.com - Transition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen DeficiencyStreetInsider.comTransition Therapeutics Inc. (Nasdaq: TTHI) announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving ...and more »
04/25/16 03:01 PMTransition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 - [PR Newswire] - TORONTO, April 25, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have undergone radical prostatectomy for organ-localized prostate cancer. Brigham and Women's Hospital (BWH) is conducting the investigator-led Phase 2 clinical study which is expected to enroll up to 125 subjects at selected specialized clinical sites including BWH.
04/24/16 07:49 AMTransition Therapeutics Ord (NASDAQ:TTHI) Sellers Covered 8.42% of Their Shorts - CCH Daily News - Transition Therapeutics Ord (NASDAQ:TTHI) Sellers Covered 8.42% of Their ShortsCCH Daily NewsThe short interest to Transition Therapeutics Ord's float is 1.39%. The stock increased 3.81% or $0.031 on April 22, hitting $0.839. About 98,077 shares traded hands or 22.25% up from the average. Transition Therapeutics Inc (USA) (NASDAQ:TTHI) has ...
04/22/16 08:53 AMLatest Analyst Ratings For Transition Therapeutics, Inc. (TTHI) - Share Trading News - Web Breaking NewsLatest Analyst Ratings For Transition Therapeutics, Inc. (TTHI)Share Trading NewsTransition Therapeutics, Inc. has a 50 day moving average of 1.03 and a 200 day moving average of 1.49. The stock's market capitalization is 31.89M, it has a 52-week low of 0.74 and a 52-week high of 9.30. The share price of the company (TTHI) was up ...Canaccord Genuity Reiterates Hold Rating for Transition Therapeutics Inc (TTHI)Web Breaking Newsall 3 news articles »
04/21/16 08:56 AMBroker Roundup For Transition Therapeutics, Inc. (TTHI) - Share Trading News - Broker Roundup For Transition Therapeutics, Inc. (TTHI)Share Trading News04/29/2014 – Transition Therapeutics, Inc. was upgraded to “sector perform” by analysts at RBC Capital. They now have a USD 5.5 price target on the stock. The share price of Transition Therapeutics, Inc. (TTHI) was down -3.09% during the last trading ...Transition Therapeutics Inc (TTHI) Lowered to Sell at Zacks Investment ResearchMas Market Newsall 6 news articles »
04/19/16 09:17 AMBiotech Stocks Inside Traders Spotlight: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Transition Therapeutics, Inc ... - WsNews 4investors - Biotech Stocks Inside Traders Spotlight: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) , Transition Therapeutics, Inc ...WsNews 4investorsLtd. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California. Transition Therapeutics, Inc. (NASDAQ:TTHI) finished the trading with negative move of -37.59% and closed the day at $0.78 which had been below its ...
04/19/16 09:17 AMAstraZeneca plc (NYSE:AZN) & Transition Therapeutics (NASDAQ:TTHI) Hot Stock's Alert - Wall Street 24 - AstraZeneca plc (NYSE:AZN) & Transition Therapeutics (NASDAQ:TTHI) Hot Stock's AlertWall Street 24Shares of Transition Therapeutics Inc (USA) (NASDAQ:TTHI) declined -39.07% to $0.780. Transition Therapeutics Inc. declared that it has received notification that Eli Lilly and Co. (“Lilly”) will not elect to advance diabetes drug candidate, TT401 into ...
04/19/16 09:17 AMActive Stocks Need to Consider- M&T Bank (NYSE:MTB), Transition Therapeutics. (NASDAQ:TTHI), GlaxoSmithKline ... - Seneca Globe - Active Stocks Need to Consider- M&T Bank (NYSE:MTB), Transition Therapeutics. (NASDAQ:TTHI), GlaxoSmithKline ...Seneca GlobeStocks of Transition Therapeutics Inc. (NASDAQ:TTHI) shows upbeat performance, Dropped -37.59% to trade at $0.78 in last session with shares volume of 52.90. Transition Therapeutics Inc. (TTHI) released on Monday that it has attain notification that ...and more »
04/18/16 08:57 AMTransition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3 - (RTTNews.com) - Transition Therapeutics Inc. (TTHI, TTH.TO), a biopharmaceutical development company, announced Monday that it has received notification that Eli Lilly and Co. ( LLY) will not elect to advance diabetes drug candidate, TT401 into Phase 3 ...
04/18/16 08:57 AMTransition Therapeutics (TTHI) Says Lilly (LLY) Won't Advance TT401 into Phase 3 - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Transition Therapeutics Inc. (Nasdaq: TTHI) announced that it has received notification that Eli Lilly and Co. ("Lilly") will not elect to advance diabetes drug candidate ...
04/18/16 08:57 AMTransition Therapeutics Inc to advance diabetes drug without Eli Lilly - Transition Therapeutics Inc (NASDAQ:TTHI, TSE:TTH) told investors that its collaborator and pharma giant Eli Lilly and Co will not advance its Type 2 diabetes drug into Phase 3 development. It means all development and commercialisation rights for TT401 ...
04/18/16 05:34 AMTransition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401 - TORONTO, April 18, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced that it has received notification that Eli Lilly and Co. ("Lilly") will not elect to advance diabetes drug ...
04/14/16 01:14 PMMaking Impressive Motion: Transition Therapeutics Inc. (NASDAQ:TTHI), Sumitomo Mitsui Financial Group (NYSE ... - Property Mentor - Making Impressive Motion: Transition Therapeutics Inc. (NASDAQ:TTHI), Sumitomo Mitsui Financial Group (NYSE ...Property MentorTransition Therapeutics Inc. (NASDAQ:TTHI) ended the last trading day at $1.24. Company weekly volatility is calculated as 9.57%. Transition Therapeutics Inc. (NASDAQ:TTHI) showed a weekly performance of 5.98%. On 13 April, Sumitomo Mitsui Financial ...and more »
04/12/16 11:50 AMAfter Last Week What Do Analysts Think Of Transition Therapeutics, Inc. (TTHI) - Share Trading News - After Last Week What Do Analysts Think Of Transition Therapeutics, Inc. (TTHI)Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Transition Therapeutics, Inc. (TTHI). The latest reports which are currently in issue on Sunday 10th of April state 0 analysts have a rating of “strong buy”, 2 analysts ...Transition Therapeutics Ord (NASDAQ:TTHI) Shorted Shares Decreased By 5.4%Business Standard TribuneTransition Therapeutics, Inc. (TTHI) - Broker UpdateRisers & Fallersall 3 news articles »
04/09/16 11:12 AMTransition Therapeutics, Inc. (TTHI) Updated Broker Price Targets - Share Trading News - Transition Therapeutics, Inc. (TTHI) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Transition Therapeutics, Inc. (TTHI). The latest reports which are currently in issue on Friday 8th of April state 0 analysts have a rating of “strong buy”, 2 analysts ...and more »
04/09/16 11:12 AMTransition Therapeutics, Inc. (TTHI) - Broker Update - Risers & Fallers - Transition Therapeutics, Inc. (TTHI) - Broker UpdateRisers & FallersCurrently 3 brokers are covering Transition Therapeutics, Inc. (TTHI), 0 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 1 “Hold”. Below are the most recently updated broker updates which include ratings and price targets for ...
04/05/16 01:22 PMTransition Therapeutics Ord (NASDAQ:TTHI) Short Interest Decreased By 5.4% - Stock Caller - Transition Therapeutics Ord (NASDAQ:TTHI) Short Interest Decreased By 5.4%Stock CallerThe stock of Transition Therapeutics Ord (NASDAQ:TTHI) registered a decrease of 5.4% in short interest. TTHI's total short ... The ratio turned negative, as 10 funds sold all Transition Therapeutics Inc (USA) shares owned while 4 reduced positions. 5 ...
03/17/16 04:01 PMTransition Therapeutics Receives Notification From NASDAQ - [CNW Group] - Transition Therapeutics Receives Notification From NASDAQ
03/01/16 03:30 PMTransition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference - [CNW Group] - Transition Therapeutics to Present at the 36th Annual Cowen Healthcare Conference
02/10/16 11:33 AMDETROIT — The moon turned blue on Tuesday and a pig was spotted flying near the Ottawa airport - winnipegfreepress.com schreibt dazu weiter: TORONTO - TORONTO (AP) _ Transition Therapeutics Inc (TTHI) on Tuesday reported a loss of $1 5 million in its fiscal second quarter On a per-share basis, the Toronto-based company said it had a loss of 4 cents In ...
02/09/16 05:29 PMTransition Therapeutics posts 2Q loss -
02/09/16 03:30 PMTransition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results - [CNW Group] - Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results
02/05/16 12:01 PMTransition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST - [CNW Group] - Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST
02/01/16 05:04 AM6:04 am Transition Therapeutics and Eli Lilly (LLY) report top line data from Phase 2 trial of diabetes candidate TT401 -
02/01/16 05:01 AMTransition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401 - [CNW Group] - Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401
01/06/16 05:01 AMTransition Therapeutics Announces Annual General Meeting Voting Results - [CNW Group] - Transition Therapeutics Announces Annual General Meeting Voting Results
12/08/15 12:15 PMTRANSITION THERAPEUTICS INC. Financials -
11/19/15 10:45 AMTransition Therapeutics to Host Investor Day November 23 in New York - [PR Newswire] - Live Webcast Beginning at 12 PM Eastern Time TORONTO, Nov. 19, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today ...
11/10/15 03:21 PMTransition Therapeutics posts 1Q loss -
11/10/15 03:01 PMTransition Therapeutics Announces First Quarter Fiscal 2016 Financial Results - [CNW Group] - Transition Therapeutics Announces First Quarter Fiscal 2016 Financial Results
11/08/15 07:26 PMAppointment of Non-Executive Director (G Pace) - [at noodls] - _ December 2008 9 November 2015 Appointment of Non-Executive Director The Board of Directors of Antisense Therapeutics Limited ('ANP' or the 'Company') is pleased to announce the appointment of Dr Gary ...
11/02/15 05:01 AMTransition Therapeutics to Hold Conference Call on First Quarter Fiscal 2016 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST - [CNW Group] - Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2016 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST
10/29/15 03:01 PMTransition Therapeutics Announces Agreement for Phase 2 Study of TT701 Drug Candidate - [PR Newswire] - TORONTO, Oct. 29, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Transition Therapeutics Ireland Limited ("TTIL") has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital (BWH). TTIL will support a Phase 2 study to evaluate selective androgen receptor modulator (SARM) drug candidate TT701 as a therapy to improve the symptoms of androgen deficiency in men with prostate cancer who have undergone a radical prostatectomy procedure. The Phase 2 clinical study is expected to enroll up to 125 subjects and will be performed at selected specialized clinical sites including BWH.
About Transition Therapeutics

Transition Therapeutics logoTransition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TTHI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.74
  • 50 Day Moving Average: $0.79
  • 200 Day Moving Average: $1.12
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $28.77M
  • Current Quarter EPS Consensus Estimate: $-0.33 EPS
Additional Links:
Transition Therapeutics (NASDAQ:TTHI) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha